Leap Therapeutics Inc (LPTX) Stock: What Does the Chart Say Wednesday?

Overall market sentiment has been high on Leap Therapeutics Inc (LPTX) stock lately. LPTX receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Leap Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on LPTX!

See Full LPTX Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With LPTX Stock Today?

Leap Therapeutics Inc (LPTX) stock is trading at $1.78 as of 1:11 PM on Wednesday, Oct 4, a gain of $0.13, or 7.81% from the previous closing price of $1.65. The stock has traded between $1.66 and $1.93 so far today. Volume today is above average. So far 1,765,294 shares have traded compared to average volume of 260,182 shares. To screen for more stocks like Leap Therapeutics Inc click here.

More About Leap Therapeutics Inc

Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. Its clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1. DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. The company is studying DKN-01 in multiple ongoing clinical trials in patients with esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, or prostate cancer. Its other clinical studies include P100, P102, P204,and P205. Click Here to get the full Stock Report for Leap Therapeutics Inc stock.